Open-label Pilot Study of Ziprasidone for Refractory Generalized Anxiety Disorder
The DOI matches its Crossref record.
Abstract
Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School, of Medicine, Philadelphia, PA, [email protected] Study results were presented at poster sessions at the annual meeting of the APA (May 1-6, 2004, New York, NY) and the NCDEU (June 1-4 2004, Phoenix, AZ).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214
“Ziprasidone Snyderman and colleagues evaluated low-dose ziprasidone in patients with treatment-resistant GAD (N = 13): ziprasidone (20 to 80 mg/day) significantly improved anxiety symptoms [99].”
BackgroundCurrent Considerations in the Treatment of Generalized Anxiety Disorder
Katzman, M. A. (2009) · CNS Drugs · doi:10.2165/00023210-200923020-00002 · Cited by 128
Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review
Bokma, W. A., Wetzer, G. A. A. M., Gehrels, J. B., Penninx, B. W. J. H., Batelaan, N. M., & Balkom, A. L. J. M. (2019) · Depression and Anxiety · doi:10.1002/da.22895 · Cited by 58
“…Prasko, Latalova, Kamaradova, & Grambal, 2016; Pallanti & Quercioli, 2006; Pollack, Otto, Kaspi, Hammerness, & Rosenbaum, 1994; Simon et al., 2006; Snyderman et al., 2005; Solbakken & Abbass, 2015, 2016; Worthington III, Kinrys, Wygant, & Pollack, 2005; Yoshinaga et al., 2016), eight RCTs…”
Metadata
- Authors
- Snyderman, S. H., Rynn, M. A., & Rickels, K.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2005-10
- Volume
- 25
- Issue
- 5
- Pages
- 497-499
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2092661365
- Cited by
- 36
- References
- 0
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Open-label Pilot Study of Ziprasidone for Refractory Generalized Anxiety Disorder. https://app.cochat.ai/papers/10.1097/01.jcp.0000177853.15910.de
- The paper
- Snyderman, S. H., Rynn, M. A., & Rickels, K. (2005). Open-label Pilot Study of Ziprasidone for Refractory Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/01.jcp.0000177853.15910.de
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.